Cognetivity Neurosciences (Cognetivity Neurosciences) COGS-to-Revenue : 0.00 (As of Oct. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences COGS-to-Revenue?

Cognetivity Neurosciences's Cost of Goods Sold for the three months ended in Oct. 2023 was $0.00 Mil. Its Revenue for the three months ended in Oct. 2023 was $0.02 Mil.

Cognetivity Neurosciences's COGS to Revenue for the three months ended in Oct. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cognetivity Neurosciences's Gross Margin % for the three months ended in Oct. 2023 was N/A%.

Cognetivity Neurosciences COGS-to-Revenue Historical Data

The historical data trend for Cognetivity Neurosciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences COGS-to-Revenue Chart

Cognetivity Neurosciences Annual Data

Trend

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

COGS-to-Revenue

Get a 7-Day Free Trial

Cognetivity Neurosciences Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Cognetivity Neurosciences COGS-to-Revenue Calculation

Cognetivity Neurosciences's COGS to Revenue for the fiscal year that ended in Jan. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.034
	=	0.00

Cognetivity Neurosciences's COGS to Revenue for the quarter that ended in Oct. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.021
	=	0.00

Cognetivity Neurosciences (OTCPK:CGNSF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cognetivity Neurosciences's Gross Margin % for the three months ended in Oct. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.021
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cognetivity Neurosciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognetivity Neurosciences (Cognetivity Neurosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

1UB:Germany CGN:Canada

Address

800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6

Website

https://www.cognetivity.com

Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences (Cognetivity Neurosciences) Headlines

From GuruFocus

Three Companies Using AI and Innovation to Lead Healthcare Sector

By ACCESSWIRE AccessWire • 04-12-2019

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire • 04-12-2019